Pharmaceutical-Grade PDE5 Inhibitor for Laboratory Research
Tadacip-20 Cipla is a pharmaceutical-grade formulation containing 20mg tadalafil citrate per tablet, designed for in-vitro laboratory investigations examining phosphodiesterase type 5 (PDE5) enzyme inhibition mechanisms. This well-characterised compound serves as a valuable research tool for scientists studying vascular biology, smooth muscle function, and cyclic nucleotide signalling pathways in controlled laboratory environments.
Researchers at Stroid UK Shop utilise this compound alongside other research chemicals from our extensive SARMs catalogue to investigate complementary molecular pathways in comprehensive research protocols.
Research Applications and Mechanisms
Tadalafil citrate functions as a selective phosphodiesterase type 5 inhibitor, preventing the degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. Laboratory studies examine how this mechanism affects nitric oxide-mediated signalling cascades and endothelial function in various tissue preparations. Research applications include investigating vascular reactivity, studying smooth muscle physiology, and examining the role of PDE5 in cellular signalling networks.
Scientists investigate this compound’s molecular interactions with other research chemicals, including compounds from our peptides collection, to understand complex physiological mechanisms in controlled experimental settings.
Product Specifications
| Active Ingredient | Tadalafil Citrate |
|---|---|
| Concentration | 20mg per tablet |
| Manufacturer | Cipla Limited |
| Formulation | Oral tablet |
| Storage Requirements | Room temperature, dry environment |
| Research Category | PDE5 Inhibitor |
Research Compliance and Safety
This product is intended exclusively for in-vitro laboratory research purposes by qualified researchers in appropriate laboratory facilities. It is not intended for human consumption, therapeutic use, or any application outside controlled scientific research environments. Researchers must follow institutional safety protocols and obtain necessary approvals before commencing studies with this compound.
